Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AUTL
CUSIPN/A
Phone44-20-3829-6230
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees126
Outstanding Shares38,790,000
Market Cap$1.15 billion
Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions
What is Autolus Therapeutics' stock symbol?
Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."
What price target have analysts set for AUTL?
4 brokers have issued 1 year price targets for Autolus Therapeutics' stock. Their predictions range from $37.00 to $38.00. On average, they expect Autolus Therapeutics' stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 37.9% from the stock's current price. View Analyst Price Targets for Autolus Therapeutics.
What is the consensus analysts' recommendation for Autolus Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Autolus Therapeutics.
Who are some of Autolus Therapeutics' key competitors?
Some companies that are related to Autolus Therapeutics include Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), argenx (ARGX), Repligen (RGEN), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Solid Biosciences (SLDB), Atara Biotherapeutics (ATRA) and Rubius Therapeutics (RUBY).
Who are Autolus Therapeutics' key executives?
Autolus Therapeutics' management team includes the folowing people:
- Dr. Christian Martin Itin, Chairman & CEO (Age 54)
- Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 46)
- Mr. Andrew J. Oakley, CFO & Sr. VP (Age 56)
- Mr. Christopher Vann, Sr. VP & COO (Age 53)
- Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 53)
When did Autolus Therapeutics IPO?
(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.
When does the company's lock-up period expire?
Autolus Therapeutics' lock-up period expires on Wednesday, December 19th. Autolus Therapeutics had issued 8,823,530 shares in its IPO on June 22nd. The total size of the offering was $150,000,010 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Who are Autolus Therapeutics' major shareholders?
Autolus Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Woodford Investment Management Ltd (4.10%), Baker BROS. Advisors LP (0.61%), Partner Fund Management L.P. (0.51%), Aquilo Capital Management LLC (0.39%), Millennium Management LLC (0.38%) and Victory Capital Management Inc. (0.31%).
Which major investors are buying Autolus Therapeutics stock?
AUTL stock was purchased by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, Baker BROS. Advisors LP, Partner Fund Management L.P., Aquilo Capital Management LLC, Millennium Management LLC, Victory Capital Management Inc., Jennison Associates LLC and Granahan Investment Management Inc. MA.
How do I buy shares of Autolus Therapeutics?
Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Autolus Therapeutics' stock price today?
One share of AUTL stock can currently be purchased for approximately $27.20.
How big of a company is Autolus Therapeutics?
Autolus Therapeutics has a market capitalization of $1.15 billion. Autolus Therapeutics employs 126 workers across the globe.
What is Autolus Therapeutics' official website?
How can I contact Autolus Therapeutics?
Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]
MarketBeat Community Rating for Autolus Therapeutics (NASDAQ AUTL)
MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote "Outperform" if you believe AUTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
